Evidence map›Paper›PMID 12618906›Full record

ArticleImmunogenetics2003

Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.

Wojciech Wiszniewski, Marie-Claude Fondaneche, Pascale Louise-Plence, Ada Prochnicka-Chalufour, Françoise Selz, Cappucine Picard, Françoise Le Deist, Jean-François Eliaou, Alain Fischer, Barbara Lisowska-Grospierre

Abstract read
PubMed Publisher
In one paragraph

Article in Immunogenetics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Clinical, immunological and genetic features in eleven Algerian patients with major histocompatibility complex class II expression deficiency.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2012
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The ankyrin repeat as molecular architecture for protein recognition.Protein science : a publication of the Protein Society · 2004
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Wojciech WiszniewskiINSERM U 429, Hopital Necker-Enfants Malades, Paris, France. wojtekw@imid.med.pl
Marie-Claude Fondaneche
Pascale Louise-Plence
Ada Prochnicka-Chalufour
Françoise Selz
Cappucine Picard
Françoise Le Deist
Jean-François Eliaou
Alain Fischer
Barbara Lisowska-Grospierre
Inserm · FRCentre National de la Recherche Scientifique · FRHôpital Necker-Enfants Malades · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MHC class II deficiency is a combined immunodeficiency caused by defects in the four regulatory factors, CIITA, RFXANK, RFX5 and RFXAP, that control MHC II expression at the transcriptional level. The RFXANK gene encodes one subunit of the heterotrimeric RFX complex that is involved in the assembly of several transcription factors on MHC II promoters. Seven different RFXANK mutations have previously been reported in 26 unrelated patients. The most frequent mutation, a 26-bp deletion (752delG-25), has been identified in 21 patients. The other mutations are all nonsense or splice-site mutations, leading to proteins lacking all or part of the RFXANK ankyrin repeat region. We report two novel missense mutations, D121V and R212X, resulting in loss of function of the gene. We investigated the in vivo effects of these mutations and of three other point mutations on the expression of the RFXANK RNA and protein. The number of RFXANK transcripts was severely reduced in all patients except one. The RFXANK protein was barely detected in two cases. In addition, guided by a structural model of RFXANK, we investigated experimental mutants of the C-terminal tyrosine 224. Substitution Y224A, but not Y224F, led to the loss of function of RFXANK. Two null mutants, D121V and Y224A, were tested in protein interaction and DNA binding assays. The D121V mutant was unable to form the RFX complex, indicating that D121 is required for RFXAP binding. The Y224A mutant formed an RFX complex that bound normally to the MHC II promoter, but did not lead to MHC class II expression, whereas Y224F RFXANK retained the wild-type function. This indicates that an aromatic ring, but not the phenyl chain of tyrosine, is necessary at position 224 for normal RFXANK function. Studies on the Y224A mutant suggest that, in addition to the RFX subunits and CIITA, another protein is essential for MHC class II expression. This protein appears to interact with the fourth ankyrin repeat of RFXANK.

Indexed as

Point MutationSequence DeletionAmino Acid SubstitutionAnkyrin RepeatBase SequenceBinding SitesCell Line, TransformedDNA-Binding ProteinsDNA, ComplementaryGenes, MHC Class IIHumansModels, MolecularPromoter Regions, GeneticProtein Structure, SecondaryProtein SubunitsRecombinant ProteinsDNA-Binding ProteinsDNA, ComplementaryProtein SubunitsRecombinant ProteinsRegulatory Factor X Transcription FactorsRFXANK protein, humanRNA, MessengerTranscription Factors

Identifiers

PMID12618906
OpenAlexW1559600834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.